New drug combo shows promise for tough cervical cancers
Disease control
Not yet recruiting
This study will observe 1,300 patients with advanced or recurrent cervical cancer who are treated with camrelizumab, famitinib, or combinations of these drugs. The goal is to see how safe and effective these treatments are in real-world settings. Patients are placed into one of s…
Sponsor: Qi Zhou • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC